Skip to main content
Clinical Trials/NCT01621984
NCT01621984
Completed
Phase 1

The Evaluation of Therapeutic Riding in Children and Adolescent With Kinetic Deficits Because of Neuromuscular Disease.

University of Ioannina1 site in 1 country60 target enrollmentJune 2012

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Neuromuscular Disease
Sponsor
University of Ioannina
Enrollment
60
Locations
1
Primary Endpoint
Change from baseline in posture control at different time points
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The purpose of this current prospective study is to assess the effects of a Therapeutic Riding exercise program conducted in patients suffering from neuromuscular disease. The exercise intervention aims at improving gross motor function, gross motor performance, balance, spasticity, posture and quality of life. Patients were randomized according to age, sex, mental ability and gross motor function. Furthermore, patients will be subdivided into categories of central nervous system (brain/ spinal cord) and peripheral (peripheral nerve or muscle) diseases. The exercise program duration will be 12 weeks, once a week with 30-40 minutes sessions. Six measurements will be conducted: the Gross Motor Function Measure, the Gross Motor Performance Measure, the Quality of life Questionnaire for Children, the Pediatric Balance Scale, the dynamic plate in combination with x-ray for posture control, the Modified Ashworth Scale for spasticity and the Wisc 3 for mental ability. The results will be collected and evaluated using the statistical programme SPSS.

Registry
clinicaltrials.gov
Start Date
June 2012
End Date
October 2016
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Avraam Ploumis

Assistant Professor of PMR, Orthopaedic Spine Surgeon

University of Ioannina

Eligibility Criteria

Inclusion Criteria

  • Children with neuromuscular disease
  • Parental consent
  • Sitting posture capability
  • Hip abduction capability on horseback
  • Ability to communicate and collaborate with the researcher

Exclusion Criteria

  • Children with Scheuermann disease
  • uncontrolled seizures (A) child with generalized seizure over 2 minutes in the last three months (B) Children who are not well-adjusted levels of antiepileptic drugs.
  • musculoskeletal disorder that may be aggravated by the movement of the horse such as atlantoaxial instability, osteoporosis etc.
  • Scoliosis \> 30 degree
  • Allergy to dust

Outcomes

Primary Outcomes

Change from baseline in posture control at different time points

Time Frame: Measures will be done: 1 two months before treatment, 2 one month before treatment, 3 one day before start of treatment, 4 six weeks after the start of treatment, 5 twelve weeks, the end of treatment 6 two months after the end of treatment.

posture control measured by the dynamic plate in combination with x-ray.

Change from baseline in balance at different time points

Time Frame: Measures will be done: 1 two months before treatment, 2 one month before treatment, 3 one day before start of treatment, 4 six weeks after the start of treatment, 5 twelve weeks, the end of treatment 6 two months after the end of treatment.

Balance measured by the Pediatric Balance Scale

Secondary Outcomes

  • Improvement in Gross Motor Function(Measures will be done: 1 two months before treatment, 2 one month before treatment, 3 just before treatment, 4 six weeks after the start of treatment, 5 twelve weeks, the end of treatment 6 two months after the end of treatment.)
  • Improvement in Quality of life(Measures will be done: 1 two months before treatment, 2 one month before treatment, 3 just before treatment, 4 six weeks after the start of treatment, 5 twelve weeks, the end of treatment 6 two months after the end of treatment.)
  • Improvement in Gross Motor Performance(Measures will be done: 1 two months before treatment, 2 one month before treatment, 3 just before treatment, 4 six weeks after the start of treatment, 5 twelve weeks, the end of treatment 6 two months after the end of treatment.)
  • Decrease of spasticity(Measures will be done: 1 two months before treatment, 2 one month before treatment, 3 just before treatment, 4 six weeks after the start of treatment, 5 twelve weeks, the end of treatment 6 two months after the end of treatment.)

Study Sites (1)

Loading locations...

Similar Trials